secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001437749-25-008139
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity reports Phase 2 data for stenoparib in advanced ovarian cancer; durable benefit in platinum-resistant patients
--------------------------------------------------------------------------------

- 5 of 15 patients stayed on therapy >4 months; 1 had confirmed complete response lasting >10 months.
- 2 patients remain on therapy >17 months; patient with primary platinum-refractory disease remained >40 weeks.
- Stenoparib well-tolerated with no bone marrow toxicity typical of first-generation PARP inhibitors.
- Clinical benefit seen in BRCA wild-type patients, supporting dual PARP/Wnt pathway inhibition.
- New Phase 2 protocol announced focusing on platinum-resistant patients with single prior chemo line.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925008139/0001437749-25-008139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925008139/allr20250317_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer